Selective Increases in HIV-Specific Neutralizing Antibody and Partial Reconstitution of Cellular Immune Responses during Prolonged, Successful Drug Therapy of HIV Infection
- 20 July 2001
- journal article
- research article
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 17 (11) , 1021-1034
- https://doi.org/10.1089/088922201300343708
Abstract
Because the immune response to HIV depends on viral gene expression, we examined the HIV-specific immune responses in persons whose viral load after highly active antiretroviral therapy (HAART) was p = 0.06; against CM237, p = 0.04). The two persons with large increases in binding antibody also had increases in primary isolate NAb. Roughly half of HAART recipients had significant increases in neutralizing antibody to the primary isolates US1 and CM237. Compared with CD4-matched, non-HAART controls, there were significant increases in NAb against the subtype B primary isolate US1 (p < 0.0009); no increases were seen against more easily neutralized primary isolate BZ167. There were no differences after HAART in antibody-directed cellular cytotoxicity (ADCC). HAART resulted in a partial restoration of lymphoproliferative responses to recall antigens (tetanus and diphtheria). New responses developed to HIV Gag p24. No patient responded to HIV Env gp160 or gp120 either before or after HAART. The data underscore the lack of functional reconstitution of HIV-specific, CD4-mediated responses despite durable suppression of viral replication. In the setting of stable anti-HIV Ab levels, the development of increased NAb in certain individuals suggests that control of the virus by HAART may assist in immune control of HIV.Keywords
This publication has 52 references indexed in Scilit:
- Anti-CD4-Binding Domain Antibodies Complexed with HIV Type 1 Glycoprotein 120 Inhibit CD4+T Cell-Proliferative Responses to Glycoprotein 120AIDS Research and Human Retroviruses, 2000
- Efficacy Testing of Recombinant Human Immunodeficiency Virus (HIV) gp160 as a Therapeutic Vaccine in Early‐Stage HIV‐1–Infected VolunteersThe Journal of Infectious Diseases, 2000
- Primary Isolate Neutralization by HIV Type 1-Infected Patient Sera in the Era of Highly Active Antiretroviral TherapyAIDS Research and Human Retroviruses, 1999
- Repeated Immunization with Recombinant gp160 Human Immunodeficiency Virus (HIV) Envelope Protein in Early HIV‐1 Infection: Evaluation of the T Cell Proliferative ResponseThe Journal of Infectious Diseases, 1999
- HIV-1 Antigen–specific and –nonspecific B Cell Responses Are Sensitive to Combination Antiretroviral TherapyThe Journal of Experimental Medicine, 1998
- Impact on the immune system of undetectable plasma HIV-1 RNA for more than 2 yearsAIDS, 1998
- Viral Culture and p24 Antigenemia of Human Immunodeficiency Virus (HIV)-Infected Individuals Correlated with Antibody Profiles Determined with Recombinant Polypeptides of All HIV-1 Open-Reading FramesThe Journal of Infectious Diseases, 1992
- The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related ComplexNew England Journal of Medicine, 1987
- Characterization of Serum Netralization Response to the Human Immunodeficiency Virus (HIV)AIDS Research and Human Retroviruses, 1987
- Qualitative Analysis of Immune Function in Patients with the Acquired Immunodeficiency SyndromeNew England Journal of Medicine, 1985